key: cord-0721072-peaua286 authors: Arslan, Yakup; Dogan, Deniz; Ocal, Nesrin; Koc, Alperen; Ayaz, Tunahan; Ozkan, Recep; Yoruk, Fatma; Esmer, Meltem Nilsen; Kosger, Sumeyye; Kadioglu, Ekin; Savasci, Umit; Cuce, Ferhat; Fidan, Gonca; Yilmaz, Gulden; Kayahan Satis, Neslihan; Bilge, Sedat; Senkal, Serkan; Tasci, Canturk; Kayir, Hakan title: The boundaries between survival and nonsurvival at COVID‐19: Experience of tertiary care pandemic hospital date: 2021-06-25 journal: Int J Clin Pract DOI: 10.1111/ijcp.14461 sha: 662f8ecdb68016a6547920821faddbbc9036c4c8 doc_id: 721072 cord_uid: peaua286 OBJECTIVE: Coronavirus disease 2019 (COVID‐19) is an emerging, fast‐spreading, highly mortal and worldwide infectious disease. The pulmonary system was defined as the main target of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), but the mortality concept of this disease presented with more severe and systemic disease. The present study investigated the relationship between the patient characteristics at the initial hospital administration and fatality in COVID‐19 patients. METHODS: In this retrospective and comparative cohort study, all the 767 hospitalised COVID‐19 patients, treated between 18 March and 15 May 2020 in the Covid Clinics of Gulhane Training and Research Hospital in Ankara, Turkey, were evaluated. RESULTS: The fatality rate was significantly increased in patients with any comorbid disease except asthma. The initial laboratory test results indicated highly significant differences according to the patient's outcome. A multifactor logistic regression analysis was performed to calculate the adjusted odds ratios for predicting patient outcomes. Being older than 60 years increased the death risk with an adjusted OR of 7.2 (95% CI: 2.23‐23.51; P = .001). The presence of a cancer and the extended duration of intensive care unit treatment were other significant risk factors for nonsurvival. Azithromycin treatment was determined as significantly reduced the death ratio in these patients (P = .002). CONCLUSION: It was revealed that being older than 60 years, presence of a cancer and extended duration of ICU treatment were the major risk factors for predicting fatality rate in hospitalised COVID‐19 patients. The novel severe acute respiratory syndrome coronavirus 2 (SARS- reported in Wuhan, Hubei Province, in January 2020. It has quickly become an emerging, serious, fast-spreading and worldwide health disaster. The 2 487 236 of people had died amongst 112 336 160 infected cases of COVID-19 disease in 218 different countries around the world until 23 February 2021. 1 Mostly the pulmonary system was defined as the main target of SARS-CoV-2, but the mortality concept of this disease presented with more severe and systemic disease including shock, multi-organ failure, pyrexia resistant to treatment and acute lung injury with acute respiratory distress syndrome. 2 The COVID-19 related fatality rate has been reported into a range between 2% and 20%, mainly depending on the availability of medical resources and economic status of the patient or country in general. 3 One of the most important issues in managing COVID-19 is the accurate and early identification of high-risk patients. Early risk stratification can help medical decision making and resource allocation; for example, transferring the high-risk patients to the intensive care unit (ICU) for close monitoring and organ support at the early stages of the disease could help to decrease the fatality rate. Although several studies have investigated the risk factors for fatality in COVID-19, a standardised systematic effort to develop prediction tools for risk stratification of the patients at an early stage would be needed. The Centers for Disease Control and Prevention reported that although individuals older than age 65 years comprise 17% of the total population in the United States, they represent 31% of the COVID-19 infections, 45% of hospitalisations, 53% of ICU admissions and 80% of the deaths caused by COVID-19. 4 Wu et al showed that the case fatality rate (CFR) is 2.3% in general population; however, it increases to 8% in 70-80 years old and 14.8% in older than 80 years age group of patients. 5 The physiological changes during ageing, having multiple age-related comorbid conditions such as heart and lung diseases, diabetes, dementia and the increased incidence of polypharmacy, have been associated with poor outcomes in older patients. 6 Together with the risk factors, several laboratory tests were consistently reported to be related to COVID-19 patient outcomes. For example, elevated C-reactive protein (CRP), creatinine, together with decreased lymphocyte count and reduced magnesium levels upon admission are proposed as the predictors of increased death in COVID-19. 7 In a recent study from our medical centre, Doganci et al showed that increased CRP, white blood cell (WBC) count and neutrophil-to-lymphocyte ratio and decreased prognostic nutritional index could be used as prognostic factors for in-hospital mortality rate of COVID-19 cases. 8 The present study was designed to investigate the broad range of factors related to fatality rate in COVID-19 cases followed as inpatient in our medical centre. The primary endpoint of the present study is investigating the demographic, clinical and laboratory risk factors for fatality rate in hospitalised COVID-19 patients. The secondary endpoint is evaluating the effects of the applied treatments to the patient outcome. Finally, we aimed to find out the odds ratios (OR) by using multivariate logistic analysis for the selected variables in order to predict nonsurvival patient characteristics in our cohort. The present study was designed as a retrospective, comparative cohort study. Between • According to the current treatment protocol, favipiravir is accepted as one of several antiviral medications to be used immediately at the onset of symptoms. • In vitro studies have demonstrated the capacity of azithromycin in reducing production of proinflammatory cytokines such as IL-8, IL-6, TNF alpha, reduce oxidative stress and modulate T-helper functions but not described in vivo studies. • The presence of a cancer and the extended duration of intensive care unit treatment were the most significant risk factors for nonsurvival together with being older than 60 years. • Azithromycin was determined as significantly reduced the death ratio in COVID-19 patients. COVID-19 by a radiologist (FC). The typical image features include ground-glass opacities (GGO), consolidation, mixed GGO and con- The data were represented as the mean ± standard error of mean Software (IBM Corp., Armonk, NY). The statistical significance was set at P < .05. The Bonferroni correction was applied when multliple comparisons were made. Between 18 March and 15 May 2020, 767 patients were hospitalised with the diagnosis of COVID-19. There were a total of 59 deaths (fatality rate was 7.69%). Demographics, medical comorbidities, chronic drug use of the patients and applied treatments were compared according to the outcomes presented in Table 1 . The gender distribution of the patients was similar, and gender had no effect on the outcome (P > .05; Table 1 ). The survived patients were significantly younger compared to nonsurvived patients (P < .001; average 50 vs. 74 years). Almost one third of all patients were over 60 years of age, and being in the older group was almost three times more common in the nonsurvived group (P < .001; 33% vs. 92%). Other factors such as body mass index (BMI), smoking status and being a health worker had no effect on the patient outcome (P values >.05). Hypertension (HT) and diabetes mellitus (DM) were the most frequently recorded comorbidities in the overall patient sample. The death rate was significantly increased in patients with a comorbid disease except asthma (Table 1) . Amongst the administered treatments during the hospitalisation, only azithromycin significantly reduced the nonsurvival rate (P < .001; Table 1 ). On the other hand, the death rate seemed significantly increased in patients treated with favipiravir or an anticoagulant drug, possibly due to the differences in treatments according to the disease severity (P values <.05). The initial laboratory test results indicated highly significant differences according to the patient outcome ( Table 2 ). In short, initial blood oxygen saturation percentage (SpO 2 ), haemoglobin and albumin levels were signifi- Table 3 ). Other significant risk factors for nonsurvival were accompanied cancers and number of days spent in ICU (P values <.05). On the other hand, azithromycin treatment was determined as it significantly reduced the death ratio in these patients (P = .002; Table 3 ). Further analyses showed that the most common cancer types in the patients were lung cancer (n = 9) and haematological cancers (n = 5). There was no significant effect of cancer type on survival (P values >.05). The half of the cancer patients were followed up at the Stage 4 disease. All the patients had chemotheraphy in the past, and 20 patients (49%) were in a current chemotherapy programme which has no significant effect on patient outcome (P > .05). We observed that the cancer patients had significantly more HT, DM, CVD and COPD (P values <.05). neurological diseases were more common in dying patients compared to the survived ones. But these comorbid conditions did not produce any significant effect on patient outcomes in the multivariate analysis. Amongst the used drugs in our sample, azithromycin was determined as the only drug that significantly improved the patient outcome. Our study confirmed that older age is the prominent predictor of fatality in hospitalised COVID-19 patients. It was consistently shown On the other hand, a study from New York area reported asthma prevalence as 4.3% in 6245 COVID-19 confirmed cases, 21 and it was even reported as low as 2.1% of 2000 patients in Italy. 22 From the early days of COVID-19 pandemic, patients with asthma attracted attention for disease severity because they were expected to be adversely affected by such a devastating respiratory syndrome. However, large-scale analyses surprisingly did not completely support that expectation. For example, UK study reported a high prevalence of asthma in their cohorts, but their analyses showed that nonasthmatic COPD but not asthma related with mortality rates in hospitalised patients. 19 Similarly, the New York study did not show any significant association between asthma and COVID-19 related in-hospital mortality rates, both in univariate analysis and multivariate analysis adjusted for age, sex, race and COVID-19. A literature review included 15 studies (n = 30 496) and data from local hospitals (n = 436) showed that asthma prevalence amongst the hospitalised COVID-19 patients was similar to asthma prevalence in the population. Asthma also did not appear to be an independent risk factor for intubation amongst these patients, even after adjusting for BMI and age, which are well-known risk factors for severity. 23 Izquierdo et al followed a different approach and analysed the 71 182 patient records with asthma in Spain. 24 They showed that COVID-19 prevalence was 1.41% amongst asthmatic patients, which seems slightly higher than the general population without asthma in the same demographical area (ie, 0.89%), but the manifestation of COVID-19 in asthmatic patients was not severe, with the low rate of hospital admissions. Our study confirmed those large-scale studies. Several factors were proposed to explain the lower prevalence of asthma in COVID-19 patients. 25 For instance, having asthma might protect against COVID-19, perhaps through a different immune response elicited by the chronic disease itself. The previous observations regarding the lower risk associated with rhinitis and eczema in asthma patients were associated with allergic sensitisation, and it was linked to lower expression of ACE-2 receptors in both upper and lower respiratory airways suggesting a potential protective effect. 26 Another possibility is that the therapies used by asthmatic patients could reduce the risk of infection or of developing symptoms leading to diagnosis. In in vitro models, inhaled corticosteroids alone or in combination with bronchodilators were shown to suppress coronavirus replication and cytokine production. 27 Depending on large-scale clinical data, Izquierdo et al concluded that intranasal corticosteroids may decrease the COVID-19 related hospitalisation rate in asthma, and biologics, such as omalizumab and mepolizumab, could be effective in preventing hospitalisations and reducing the death rates in this patient group, even these drugs were used at more severe asthma cases. 21 Prospective clinical studies for testing those observations and better understanding these relationships would be beneficial for developing better preventive approaches and/or treatments. The biochemical characteristics of the patients measured during initial admission showed significant differences according to their clinical outcome and fatality rate. We tried to create an independent linear regression model for predicting several different clinical outcomes such as length of hospital stays by using laboratory variables. We also tried data transformation approaches, coding the variables as high or low according to their laboratory or calculated cut-off values using receiver operating characteristic curve analysis. 31 We showed that LDH levels in nonsurvivors were almost two times higher than the survived patients (459 ± 48 vs. 259 ± 4 U/L), and our results support the relationship between increased LDH levels and poor outcome in COVID-19 patients. Our results were in line with other laboratory test results observed as the indicators of poor prognosis such as, decreased blood albumin levels, 32 decreased hemoglobin, 33 increased ALT and AST, 34 increased urea and creatinine, 35 increased WBC, neutrophil count, CRP levels, 36 highly increased d-dimer 37 and ferritin. 38 In addition to these widely replicated predictors for poor outcome, we observed extremely increased proBNP and troponin levels in nonsurvived patients. In the present study, mean troponin levels increased twofolds in survivors, but in nonsurvivors the increase was 29-folds. For proBNP, we also observed a threefold increase in survivors compared to a 10-fold increase in nonsurvivors. These two parameters indicate myocardial stress and damage. They are frequently elevated amongst patients with severe respiratory illnesses typically in the presence of heart failure, and they are associated with an unfavourable course amongst the COVID-19 patients. 39 Recently, a cohort of 872 confirmed COVID-19 cases was evaluated for cardiac markers, and increased troponin and proBNP levels during initial admission were found as independent and complementary predictors of mortality or the need for mechanical ventilation. 40 That study reported a high prevalence (34.6%) of cardiac injury in COVID-19 patients and showed that proBNP improved the prognostic accuracy of troponin for the patient outcome. Together with our results, these studies imply that the measurement of biomarkers for cardiac damage, such as troponin and proBNP, during the initial admission may help to identify a subset of patients with a high risk of poor prognosis. showed that high viral load was independently associated with mortality and intubation. 47 Thus, early administration of favipiravir should be highly important to achieve a significant effect on viral replication. Our study did not show a significant effect of favipiravir on survival rates of the patients in multivariate analysis. In univariate analysis, favipiravir treated patients were significantly higher in the nonsurvived group, probably because it was prescribed for only severe patients according to the treatment protocol effective during the time period that study performed. According to the current treatment protocol, favipiravir is accepted as one of several antiviral medications to be used immediately at the onset of symptoms. The present study should be evaluated under several limitations. First, the study was designed as a retrospective cohort study in a single-centre setting; thus, the data were not collected a priori fashion, and we could not evaluate all variables for all the patients. Second, the treatment protocol approved by the Turkish Ministry of Health has been updated several times since the study data were collected, and the results reflect the conditions relatively early and limited time frame of the pandemic. Of note, not all the patients were initially confirmed using PCR test, and the decision to include clinically diagnosed COVID-19 cases was supported by a radiological imaging test, namely, CT scans of lungs. The present study confirms that being older than 60 years is the major risk factor for poor outcome in COVID-19 disease. In our sample, more than 90% of the nonsurvived patients were older than 60 years old. Recent observations indicate that the fatality rate is decreasing compared to the initial months of the COVID-19 pandemic. The fast response of the health systems, sharing the scientific information globally and fast, seems to be contributed to the reduction of fatality rates. We also showed that all mentioned comorbidities, except asthma, were more common amongst the nonsurvivors. Multivariate logistic regression analysis revealed that accompanied cancer and length of ICU stay, in addition to being older than 60 years, are the additional risk factors for predicting fatality rate in hospitalised COVID-19 patients. The prominent solution for the COVID-19 pandemic seems to vaccinate more than half of the world population. During that period, patients with high risk for nonsurvival, defined as being older than 60 years and accompanied cancer patients should be immediately evaluated for early diagnosis and current treatments. We would like to thank all the healthcare professionals working devotedly in the COVID-19 clinics and intensive care units of Health Sciences University, Gulhane Training and Research Hospital. This study has emerged thanks to them. All the authors declare no conflict of interest. YA is the guarantor of the content of the manuscript, including the data and analysis. YA, CT, NO, AK and DD designed and performed research; HK analysed the data; YA and HK wrote the manuscript; Coronavirus Update (Live): 112,336,160 Cases and 2,487,236 Deaths from COVID-19 Virus Pandemic Covid-19 in critically ill patients in the seattle region-case series Decomposing differences in coronavirus disease 2019-related case-fatality rates across seventeen nations. Pathog Glob Health How I treat disseminated intravascular coagulation Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia Platelet activation is associated with myocardial infarction in patients with pneumonia Mortality risk factors among hospitalized COVID-19 patients in a major referral A new COVID-19 prediction scoring model for in-hospital mortality: experiences from turkey, single center retrospective cohort analysis Turkish Republic Ministry of Health Science Board 3 Rd. Treatment Management of Adult Covid-19 Patients. MEDICAL GUIDE OF COVID-19 (SARS-CoV2 INFECTIOUS). Treatment Management of Adult Covid-19 Patients Why does COVID-19 disproportionately affect older people? Aging Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study Clinical characteristics of patients who died of coronavirus disease 2019 in China Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Comorbidities associated with mortality in 31,461 adults with COVID-19 in the United States: a federated electronic medical record analysis Mortality in patients with cancer and coronavirus disease 2019: a systematic review and pooled analysis of 52 studies Mortality in hospitalized patients with cancer and coronavirus disease 2019: a systematic review and meta-analysis of cohort studies COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO clinical characterisation protocol: prospective observational cohort study Impact of comorbid asthma on severity of coronavirus disease (COVID-19) The impact of asthma on mortality in patients with COVID-19 Asthma in a large COVID-19 cohort: prevalence, features, and determinants of COVID-19 disease severity Asthma in COVID-19 hospitalizations: an overestimated risk factor? The impact of COVID-19 on patients with asthma. medRxiv Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection? Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2 Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells Association between hypoxemia and mortality in patients with COVID-19 Lactate kinetics reflect organ dysfunction and are associated with adverse outcomes in intensive care unit patients with covid-19 pneumonia: preliminary results from a greek single-centre study An historical approach to the diagnostic biomarkers of acute coronary syndrome Lactate dehydrogenase level as a COVID-19 severity marker The effectiveness of early anticoagulant treatment in Covid-19 patients COVID-19: hemoglobin, iron, and hypoxia beyond inflammation. a narrative review Relationship between COVID-19 infection and liver injury: a review of recent data COVID-19 and the kidneys: an update Abnormal immunity of non-survivors with COVID-19: predictors for mortality d-dimer as a biomarker for disease severity and mortality in COVID-19 patients: a case control study Hyperferritinemia in critically ill COVID-19 patients-is ferritin the product of inflammation or a pathogenic mediator? ST-Segment elevation in patients with Covid-19-a case series Letter to the editor Treatment Management of Adult Covid-19 Patients. MEDICAL GUIDE OF COVID-19 (SARS-CoV2 INFECTIOUS) Macrolides and viral infections: focus on azithromycin in COVID-19 pathology Azithromycin for COVID-19: more than just an antimicrobial? Azithromycin modulates immune response of human monocyte-derived dendritic cells and Cd4+ T cells Azithromycin in the treatment of COVID-19: a review Role of favipiravir in the treatment of COVID-19 Impact of severe acute respiratory syndrome coronavirus 2 viral load on risk of intubation and mortality among hospitalized patients with coronavirus disease 2019 The boundaries between survival and nonsurvival at COVID-19: Experience of tertiary care pandemic hospital YA, DD, NO, AK, TA, RO, FY, MNE., SK, EK, US, FC, GF, GY, NKS, SB, SS and CT collected the data; all the authors (YA, DD, NO, AK, TA, RO, FY, MNE., SK, EK, US, FC, GF, GY, NKS, SB, SS, CT and HK) approved the final manuscript. The data that support the findings of this study are available from the corresponding author upon reasonable request.